Boehringer Ingelheim Reports Real-World Data for Spiriva Respimat (tiotropium bromide) Inhalation Spray 1.25mcg in Patients with Asthma

 Boehringer Ingelheim Reports Real-World Data for Spiriva Respimat (tiotropium bromide) Inhalation Spray 1.25mcg in Patients with Asthma

Boehringer’s Ofev (nintedanib) Receives FDA’s Advisory Committee Recommendation for Systemic Sclerosis Associated ILD

Shots:

  • The real-world data involves assessing of Spiriva Respima Inhalation Spray 1.25mcg + combination inhaled corticosteroid and long-acting beta2-agonist (ICS+LABA) vs increased dose of ICS+LABA or continuing high dose of ICS+LABA in patients with asthma
  • The study resulted in 73% lower exacerbation rates and 76% lower hospitalization rates in comparison to increased dose of ICS+LABA for 12 months
  • Spiriva Respimat (tiotropium bromide) is a 1.25mcg long term once-daily maintenance treatment of asthma for 6 years and older

Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post